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OBJECTIVE—Cholecystokinin (CCK) is released in response to
lipid intake and stimulates insulin secretion. We hypothesized
that CCK deﬁciency would alter the regulation of insulin secretion
and glucose homeostasis.
RESEARCH DESIGN AND METHODS—We used quantitative
magnetic resonance imaging to determine body composition and
studied plasma glucose and insulin secretion of CCK gene knock-
out (CCK-KO) mice and their wild-type controls using intraperi-
toneal glucose and arginine infusions. The area of anti-insulin
staining in pancreatic islets was measured by immunohistochemistry.
Insulin sensitivity was assessed with euglycemic-hyperinsulemic
clamps.
RESULTS—CCK-KO mice fed a low-fat diet had a reduced acute
insulin response to glucose but a normal response to arginine and
normal glucose tolerance, associated with a trend toward greater
insulin sensitivity. However, when fed a high-fat diet (HFD) for
10 weeks, CCK-KO mice developed glucose intolerance despite
increased insulin sensitivity that was associated with low insulin
secretion in response to both glucose and arginine. The deﬁ-
ciency of insulin secretion in CCK-KO mice was not associated
with changes in b-cell or islet size.
CONCLUSIONS—CCK is involved in regulating insulin secre-
tion and glucose tolerance in mice eating an HFD. The impaired
insulin response to intraperitoneal stimuli that do not typically
elicit CCK release suggests that this hormone has chronic effects
on b-cell adaptation to diet in addition to acute incretin actions.
Diabetes 60:2000–2007, 2011
O
besity and type 2 diabetes are epidemic in both
developing and developed countries, and con-
sumption of high-fat diets (HFDs) is thought to
b eac o n t r i b u t i n gf a c t o r .I np a r t i c u l a r ,c o n s u m p -
tion of an HFD promotes excess energy intake and con-
tributes to the development of obesity and insulin resistance
(1) and to abnormalities of fat metabolism (2). An HFD also
stimulates the release of gastrointestinal hormones in-
cluding cholecystokinin (CCK), glucose-dependent insu-
linotropic polypeptide (GIP) and glucagon-like peptide-1
(GLP-1) (3–5), all of which are secreted from the intestine
as ingested food is being processed for absorption. Each of
these gut hormones enhances insulin secretion and facili-
tates glucose tolerance (6).
CCK is secreted by intestinal I cells in response to
consumption of lipid and is involved in modulating in-
testinal motility, stimulating pancreatic enzyme secretion,
enhancing gall bladder contraction, and regulating meal
size (2,7,8). Pure preparations of natural porcine CCK, the
synthetic octapeptide of CCK (CCK-8), or synthetic caerulein,
which contains a COOH-terminal pentapeptide identical to
CCK, have all been found to stimulate insulin secretion in
vivo and in vitro (9,10). CCK-8 and CCK-33 are potent stimuli
for insulin release, an effect mediated by the CCK1-receptor
(CCK1R) both in vitro and in animal models (11–13). Al-
though the role of CCK action on insulin secretion is con-
troversial in healthy humans (14,15), there is evidence that
CCK decreases postprandial glucose levels and potentiates
increased insulin levels in humans with type 2 diabetes
(15,16). CCK also potentiates arginine- and amino acid–
induced insulin in normal human subjects (17). To clarify
the role of CCK in insulin and glucose homeostasis, we used
mice with a targeted global deletion of the CCK gene (CCK
knockout [CCK-KO]) mice and their wild-type controls.
RESEARCH DESIGN AND METHODS
The CCK-KO mice were back-crossed for more than 10 generations onto
a C57BL/6 J genetic background, and all mice were genotyped by PCR analysis
of tail DNA (18). Male CCK-KO mice and wild-type controls (C57BL/6
J background) were generated in an Association for Assessment and Accredi-
tation of Laboratory Animal Care International–accredited facility under con-
ditions of controlled illumination (12:12-h light-dark cycle; lights on from 0600 to
1800 h) and temperature (22°C).
CCK-KO and wild-type mice were housed individually beginning at 9 weeks
of age. All animals received free access to either a low-fat diet (LFD) (5% fat
content) or a matched HFD (20% butter fat by weight; Research Diets, New
Brunswick, NJ) and water starting at 10 weeks of age for 10 weeks (19). Body
weight and food intake were weighed by using a top-loading balance (60.01 g,
Adenturer SL; Ohaus, Pine Brook, NJ). All animal protocols were approved by
the University of Cincinnati Institutional Animal Care and Use Committee.
Intraperitoneal glucose and arginine administration. After a 5-h fast, wild-
type and CCK-KO mice (n = 8/group) were injected i.p. with 2 mg/g body wt
glucose (Sigma, St. Louis, MO) in saline. Tail blood was collected prior to
glucose administration and at 15, 30, 60, and 120 min thereafter. On a separate
day, wild-type and CCK-KO mice (n = 8/group) were injected i.p. with 4.8
mmol/kg body wt arginine (Sigma) in saline following 5-h fasting. Blood was
collected before arginine was given, and 5, 10, 15, 20, 30, and 60 min afterward.
Plasma glucose was determined using a Freestyle glucometer (Abbot Diabetes
Care, Alameda, CA).
Insulin, glucagon, leptin, and adiponectin measurements. Plasma insulin,
leptin, and adiponectin were determined using commercial enzyme-linked im-
munosorbent assay kits, and glucagon was determined by mouse endocrine
LINCOplex kits (Millipore, St. Charles, MO). All samples were processed
according to manufacturers’ protocols. Brieﬂy, 10-mL plasma samples with 1%
dipeptidyl peptidase IV (DPPIV) inhibitor were added to each well of a micro-
titer plate precoated with antipeptide monoclonal antibodies or mixed beads,
and the detection antibody was added to the captured molecules. After in-
cubation, absorbance was measured with either a microplate reader (Synergy
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ORIGINAL ARTICLEHT; BioTek Instruments, Richmond, VA) or a Luminex instrument (LX200;
Millipore, Austin, TX). The ﬁnal concentrations were calculated using standards
provided with the enzyme-linked immunosorbent assay kit and Luminex kit.
Fat and lean body masses. Fat and lean masses were determined using an
EchoMRI whole-body composition analyzer (Houston, TX) (20). The EchoMRI
is a quantitative nuclear magnetic resonance instrument that provides precise
and noninvasive measurements of whole-body composition parameters that
include total body fat and lean mass in living rodents.
Immunoﬂuorescent microscopy and morphometric analysis. The pan-
creata of wild-type and CCK-KO mice (n = 4/group) were collected from 5-h
fasted mice and ﬁxed in 4% paraformaldehyde for 30 min, followed by in-
cubation in 30% sucrose overnight at 4°C (21). Cryosections (8 mm) were cut
and immunostained with rabbit anti-insulin (1:200, sc-9168; Santa Cruz Bio-
technology). After being washed with PBS, sections were incubated with Cy5-
conjugated goat anti-rabbit antibody (Jackson ImmunoResearch Laboratory,
West Grove, PA). Sections were viewed under a Nikon confocal microscope
(Nikon DECLIPSE C1; Nikon, Tokyo, Japan). Images of islets were captured,
and islet area (n = 34 for wild-type mice and n = 31 for CCK-KO mice) was
subjected to morphometric analysis using MetaMorph Image Analysis soft-
ware (Molecular Devices, Downingtown, PA).
Euglycemic-hyperinsulinemic clamp. CCK-KO and wild-type mice were
anesthetized with ketamine and xylazine (90 mg/kg and 8 mg/kg). A chronic
indwelling catheter was inserted into the right external jugular vein and ex-
ternalized behind the head (22), and mice were allowed to recover for at least 4
days before study. Following a 5-h fast, a primed continuous infusion of insulin
(bolus of 62 mU/kg, followed by 3.5 mU/min/kg; Novolin Regular, Novo Nor-
disk, Clayton, NC) was given to raise plasma insulin levels as previously
described (22). A bolus of 10 mCi of [U-
14C]2-deoxy-d-glucose (American
Radiolabeled Chemicals, St. Louis, MO) was infused at t = 75 min to allow the
determination of glucose uptake (Rg) in speciﬁc tissues. For tail vein sam-
pling, mice were restrained in a Tailveiner (Braintree Scientiﬁc, Braintree,
MA). Blood samples (;30 mL) were taken to determine plasma glucose levels
and tracer activity at time t = 0, 30, 60, 80, 90, 100, 110, and 120 min. Additional
blood (;40 mL) was taken at t = 0, 100, and 120 min to determine basal and
clamped insulin levels. All erythrocytes from the collected blood samples were
washed in saline and infused back into the mice to minimize anemia. At the
conclusion of the studies, mice were killed and liver, fat pads, and skeletal
muscle were quickly dissected. Another cohort of animals (n =3 –4/group) was
used to determine basal glucose turnover rate. Brieﬂy, 5-h fasted animals were
infused with a bolus of tracer glucose (6.24 mCi per animal), followed by
a continuous infusion of 0.1 mCi/min of [
3H]glucose, and tail blood was col-
lected at 30, 50, 60, 70, 80, and 90 min for determining glucose and insulin
levels. Mean glucose turnover rate was determined by the average rate of
appearance of [
3H]glucose at 60–90 min.
Calculationsand statistical analysis. Glucose responses to the intraperitoneal
glucose tolerance test (IPGTT), and insulin secretion after intraperitoneal glu-
cose or arginine, were computed as the average increment above basal for
the values after injection. All values are expressed as means 6 SE. Parametric
statistical analyses, one-way ANOVA and two-way ANOVA, followed by
Bonferroni posttest for multiple comparisons, were analyzed by GraphPad
Prism (version 5.0; San Diego, CA). Differences were considered signiﬁcant
relative to the wild-type mice at the same time point if P values were , 0.05.
RESULTS
For mice fed the LFD, initial/ﬁnal body weight and body
lean/fat mass in CCK-KO mice (n = 9/group) were compa-
rable with those of wild-type mice (Supplementary Table 1).
For mice fed the HFD, initial body weight and lean mass in
CCK-KO mice were signiﬁcantly less than those in wild-type
mice. Although mice fed the HFD had increased body
weight and fat mass, the CCK-KO mice remained signif-
icantly leaner and had less fat than wild-type mice (P ,
0.05 for both). Fasting plasma glucose, insulin, glucagon,
leptin, and adiponectin were comparable in CCK-KO and
wild-type mice fed the LFD or the HFD (Table 1).
Insulin secretion and glucose metabolism on an LFD.
Prior to the IPGTT, CCK-KO mice had comparable basal
plasma glucose and insulin as wild-type mice after a 5-h
fast (Fig. 1A and C). During the intraperitoneal glucose
infusion, the CCK-KO mice had comparable plasma glu-
cose curves and mean area under the curve (AUC) for
plasma glucose but signiﬁcantly reduced insulin at 15 min
compared with the wild-type mice (Fig. 1A–C). The insulin
and glucose responses to arginine infusion were similar in
the CCK-KO and wild-type animals (Fig. 1D–F).
The body weight and fat mass of mice in the two geno-
types fed the LFD and used in the euglycemic clamp (n =6
per group) were not different (Table 2). Basal insulin in the
CCK-KO mice was lower than that in the wild-type mice,
but the difference was not signiﬁcant (Table 2). During the
clamp, plasma insulin and glucose reached steady state by
80 min and were similar for both groups (Fig. 2A; Table 2).
The mean overall glucose infusion rate (GIR) at steady
state in the clamp (90–120 min) tended to be increased
(P = 0.06) compared with that of the wild-type mice (Fig.
2B and C). The tracer estimates of Rg in the epididymal
(visceral) and inguinal white adipose tissue, as well as for
soleus, tibialis anterior, and extensor digitorum longus
muscles, were comparable for the two groups (Fig. 2D).
These ﬁndings suggest that whole-body insulin sensitivity
may be increased in the CCK-KO compared with wild-type
animals, and may account for the normal intraperitoneal
glucose tolerance in the presence of reduced glucose-
stimulated insulin secretion. However, glucose uptake
by skeletal muscle and adipose tissue does not explain
the trend toward increased insulin sensitivity in CCK-KO
mice.
Insulin secretion and glucose metabolism on an HFD.
Prior to the IPGTT, basal plasma glucose and insulin were
similar in the CCK-KO and wild-type mice (Fig. 3A and C).
During the IPGTT, CCK-KO mice were glucose intolerant
(Fig. 3A and B) with signiﬁcantly reduced insulin secretion
relative to the control animals maintained on HFD (P ,
0.0001) (Fig. 3C). Relative to mice fed the LFD, wild-type
mice fed the HFD had signiﬁcantly increased insulin and
reduced plasma glucose in response to the arginine chal-
lenge (Figs. 1 and 3). However, the CCK-KO mice on HFD
had less arginine-induced insulin release compared with
the wild-type controls (Fig. 3D–F).
TABLE 1
Plasma parameters in CCK-KO mice after a 10-week period of LFD or HFD
LFD HFD
Wild-type CCK-KO Wild-type CCK-KO
Glucose (mg/dL) 144.65 6 3.64 150.33 6 6.15 163.17 6 8.00 156.00 6 8.10
Insulin (ng/mL) 0.61 6 0.14 0.57 6 0.08 1.09 6 0.21 0.88 6 0.14
Glucagon (pg/mL) 58.10 6 9.36 69.54 6 10.21 36.43 6 2.54 36.59 6 3.64
Leptin (ng/mL) 1.53 6 0.43 2.29 6 0.63 5.83 6 0.89* 3.49 6 0.37
Adiponectin (mg/mL) 31.56 6 8.19 28.64 6 7.11 45.24 6 1.78 43.95 6 1.87
Data are means 6 SEM. Plasma in CCK-KO and wild-type mice (n =7 –10/ group) was collected after a 5-h fast following either a 10-week LFD
or an HFD at 10 weeks of age. *Signiﬁcant difference (P , 0.05) compared with LFD-treated wild-type controls.
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and used for the euglycemic clamp had comparable body
weight and body composition, thus minimizing the possi-
bility that there would be an effect of body weight or fat
mass on insulin sensitivity (Table 2). During the clamp
studies, CCK-KO mice required more exogenous glucose
to maintain euglycemia relative to wild-type mice (Fig. 4B),
and the mean GIR at 90–120 min in the CCK-KO mice was
signiﬁcantly higher than in the wild-type mice (P , 0.05)
(Fig. 4C). Interestingly, insulin sensitivity in the CCK-KO
mice was similar whether they were receiving an LFD or
HFD (Supplementary Fig. 1E). In contrast, the mean GIR
was less in the wild-type mice on an HFD than in the wild-
type mice on an LFD. Despite the changes in insulin sen-
sitivity, basal glucose turnover on LFD and HFD was similar
in wild-type and CCK-KO mice (Supplementary Fig. 1C
and D), indicating that CCK is involved in the modulation of
insulin sensitivity. These ﬁndings suggest that unlike wild-
type mice, CCK-KO mice did not develop diet-induced in-
sulin resistance. The Rg in the white adipocytes and skeletal
muscles of the CCK-KO and wild-type mice was reduced
comparably following 10 weeks on the HFD (Fig. 4D).
These ﬁndings imply that although CCK-KO mice are pro-
tected against diet-induced insulin resistance, the HFD causes
as u f ﬁcient impairment of insulin secretion in these animals
to cause glucose intolerance.
The islets of CCK-KO mice maintained on an HFD were
of a size comparable to the size in islets of wild-type mice
as determined by the area of anti-insulin staining in pan-
creatic islets by immunohistochemistry (Fig. 5). These
FIG. 1. IPGTT and arginine stimulation test (AST) in mice fed the LFD. IPGTT (2 mg/g body wt) in 5-h–fasted wild-type and CCK-KO mice
maintained on an LFD. A: Plasma glucose. B: Means of glucose AUC. C: Plasma insulin over 120 min. Arginine stimulation test (4.8 mmol/kg body wt
i.p.) in 5-h–fasted mice maintained on an LFD. D: Plasma glucose. E: Plasma insulin. F: Mean insulin AUC over 60 min. Data are expressed as
means 6 SEM. *Signiﬁcant differences relative to the wild-type groups at the same time point (P < 0.05).
INSULIN SECRETION IN CCK-KO MICE
2002 DIABETES, VOL. 60, JULY 2011 diabetes.diabetesjournals.orgresults suggest that reduced b-cell number is not a factor
in the reduced level of glucose- or arginine-induced insulin
secretion in the CCK-KO mice.
DISCUSSION
Patients with type 2 diabetes have relative b-cell insuf-
ﬁciency and impaired insulin-dependent stimulation of
glucose disposal in skeletal muscle and adipocytes as well
as impaired suppression of hepatic glucose production
(23). We hypothesized that the gut hormone CCK might be
important in some of these defects. The absence of CCK
increased insulin sensitivity both in the setting of LFD and
HFD independent of body weight or adiposity. Our ﬁnd-
ings also implicate CCK in the stimulation of insulin se-
cretion, although this effect was dependent on diet. The
normal arginine response in CCK-KO mice, coupled with
normal intraperitoneal glucose tolerance, suggests that
islet secretion in these animals is appropriate. However,
despite increased insulin sensitivity, CCK-KO animals were
glucose intolerant when maintained on a chronic HFD, and
this was associated with deﬁcient insulin secretion in re-
sponse to both glucose and arginine. These ﬁndings sup-
port a role for CCK, a gut hormone strongly inﬂuenced by
lipid ingestion, in the b-cell adaptation to high-fat feeding
and increased body adiposity. The fact that insulin secre-
tion in CCK-KO mice was impaired in response to in-
traperitoneal stimuli that do not stimulate CCK release
suggests a role for CCK on b-cell function beyond that of
an acute secretagogue.
We used a global CCK-KO mouse model to study the
effect of endogenous CCK in glucose homeostasis in the
current study. As previously reported, these animals
appeared phenotypically normal (24) and had body weight;
adiposity; and plasma glucose, insulin, glucagon, leptin,
TABLE 2
Body weight, body composition, and insulin level during the euglycemic-hyperinsulinemic clamp
LFD LFD
Wild-type CCK-KO Wild-type CCK-KO
Initial body weight (g) 26.50 6 1.04 24.38 6 0.52 25.13 6 0.94 24.37 6 1.03
Final body weight (g) 28.25 6 1.11 26.63 6 0.44 30.92 6 1.67 28.60 6 0.52
Final fat mass (g) 1.79 6 0.31 1.40 6 0.13 5.02 6 0.78* 4.64 6 0.53*
Final lean mass (g) 24.31 6 1.09 23.25 6 0.45 24.96 6 1.41 24.74 6 0.82
Basal insulin (ng/mL) 0.57 6 0.08 0.34 6 0.05 0.62 6 0.10 0.77 6 0.16
Clamp insulin (ng/mL) 1.84 6 0.15 1.56 6 0.37 2.00 6 0.25 2.00 6 0.20
Data are means 6 SEM. Body weight and body composition in CCK-KO and wild-type mice (n = 6/group) were measured before and after
either a 10-week LFD or a 10-week HFD at 10 weeks of age. Plasma insulin and glucose was determined at baseline and during a euglycemic-
hyperinsulinemic clamp study. *Signiﬁcant difference (P , 0.05) relative to LFD-treated wild-type mice in one-way ANOVA with Bonferroni
posttest.
FIG. 2. Euglycemic-hyperinsulinemic clamps in mice fed an LFD. A: Blood glucose levels. B: GIR. C: Means of GIR at 90–120 min during the
euglycemic clamp. D: Rg into selected tissues. Data are expressed as means 6 SEM for six animals per group. *Signiﬁcant differences relative to
the wild-type mice (P < 0.05).
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We used two distinct means of stimulating the b-cells be-
cause CCK has been reported to potentiate both glucose-
and arginine-induced insulin (11,17,25,26). The CCK1R is
present in pancreatic b-cells (27), and the action of CCK
on insulin secretion is mediated via the CCK1R pathway
(28). Although the CCK-KO mice on an LFD had lower
glucose-stimulated insulin secretion than the wild-type
mice, they had comparable glucose tolerance. The fact that
these animals were more insulin sensitive during a glucose
clamp suggests that the insulin response to intraperitoneal
glucose is appropriately reduced to accommodate greater
whole-body insulin action (29). The normal insulin response
to intraperitoneal arginine in LFD-fed CCK-KO animals is
consistent with this interpretation and suggests that with
this diet, CCK is not necessary for normal b-cell function.
Maintenance on the HFD increased adiposity in wild-
type and CCK-KO mice but did not affect fasting insulin or
glucose. After 10 weeks on the HFD, CCK-KO mice gained
less body weight and fat mass than wild-type mice, con-
sistent with our previous observation in these animals at
different ages (30). Further, glucagon, leptin, and adipo-
nectin, factors that inﬂuence insulin sensitivity (31,32),
were also not altered in CCK-KO mice fed the HFD rela-
tive to wild-type controls, although HFD plasma leptin
was appropriately increased in the wild-type mice fed the
HFD relative to those fed the LFD. Consistent with the
lack of weight gain and the ﬁndings in mice on an LFD, the
CCK-KO mice fed an HFD were more insulin sensitive than
the wild-type controls. Despite this, they had impaired
glucose tolerance associated with almost absent insulin
responses to intraperitoneal glucose and arginine. These
ﬁndings support a role for CCK in the b-cell adaptation to
high-fat feeding and increased body adiposity. The impor-
tance of this role is underscored by the fact that in the
absence of CCK, insulin secretion was insufﬁcient to
FIG. 3. IPGTT and arginine stimulation (AST) tests in mice fed the HFD. IPGTT (2 mg/g body wt) in 5-h–fasted wild-type and CCK-KO mice
maintained on an HFD. A: Plasma glucose. B: Means of glucose AUC. C: Plasma insulin over 120 min. Arginine stimulation test (4.8 mmol/kg body
wt i.p.) in 5-h–fasted mice maintained on an HFD. D: Plasma glucose. E: Plasma insulin. F: Insulin AUC over 60 min. Data are expressed as means 6
SEM. *Signiﬁcant differences relative to the wild-type groups at the same time point (P < 0.05).
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sulin action.
CCK is released in response to enteral stimuli, par-
ticularly protein and lipid-containing meals, but does not
increase in the circulation in response to intravenous
or intraperitoneal glucose or arginine (4,33,34). Previous
work has demonstrated that HFD increases plasma insulin
and CCK in rats and healthy men (35,36), making this
perturbation a logical stressor of CCK-KO animals. We did
not formally test the incretin action of CCK in this study,
in that we did not measure insulin secretion stimuli that
would acutely stimulate CCK release from I-cells. How-
ever, our ﬁndings suggest that CCK is necessary for b-cell
adaptation to high-fat feeding and that this effect can be
detected even in the absence of elevated circulating plasma
CCK or increased CCK release. Because an examination of
the islets in the CCK-KO animals did not demonstrate
changes in islet number or size, the implication from our
FIG. 4. Euglycemic-hyperinsulinemic clamps in mice fed an HFD. A: Blood glucose levels. B: GIR. C: Means of GIR at 90–120 min during the
euglycemic clamp. D: Rg into selected tissues. Data are expressed as means 6 SEM for six animals per group. *Signiﬁcant differences relative to
the wild-type mice (P < 0.05).
FIG. 5. Pancreatic morphology in fasted mice on an HFD. A: Anti-insulin islet area. B: Pancreatic islet mass stained with anti-insulin. Data are
expressed as means 6 SEM for four animals per group. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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the chronic absence of CCK. This is a novel ﬁnding with
clinical relevance because b-cell adaptation to obesity is
now thought to be an essential compensation to maintain
glucose homeostasis.
Surprisingly, insulin sensitivity was increased in the
absence of CCK. The GIR in the CCK-KO mice on an LFD
did not reach statistical signiﬁcance, but the magnitude of
the difference with wild-type controls, taken in the context
of the ﬁndings with HFD, suggests an underpowered ob-
servation. After 10 weeks on an HFD, the insulin sensitivity
in the CCK-KO mice was signiﬁcantly higher than that of
the wild-type animals. Wild-type mice maintained on the
HFD had a 35.7% decrease in GIR relative to LFD-treated
wild-type controls. In contrast, the GIR in the CCK-KO
mice was reduced by only 16.1% relative to that in LFD-
treated CCK-KO mice. Therefore, although maintenance
on the HFD reduced insulin sensitivity in wild-type mice,
the CCK-KO mice were less affected. Because we used mice
from the two genotypes with comparable body weight and
fat mass in the clamp study, adiposity per se is not likely to
contribute to the greater insulin sensitivity in the absence
of CCK. There is little support in the literature for direct
effects of CCK on insulin sensitivity, making this a novel
ﬁnding. In apparent contrast with our phenotype, Otsuka
Long Evans Tokushima Fatty rats, which are genetically
deﬁcient in functioning CCK1R, are obese and diabetic
(37). However, the nature of the genetic defect in these
rats is not clear.
The increased whole-body insulin sensitivity in the
CCK-KO mice was not explained by the results of Rg
measurements in white adipocytes and skeletal muscle.
Intraduodenal administration of CCK has been reported
to decrease hepatic glucose production, ruling out the
possibility that the improved insulin sensitivity of CCK-KO
mice is secondary to the lack of intraduodenal CCK action
(38). Recent evidence suggests that hepatic insulin sensi-
tivity is regulated by the brain as well as by islet hormones
and nutrient substrates (39). Our previous data have shown
that CCK-KO mice have impaired fat absorption relative to
wild-type mice following an HFD (30), and CCK-KO mice
had a signiﬁcant reduction of total hepatic fatty acids, es-
pecially palmitic acid and oleic acid (data not shown). It is
possible that less hepatic lipid accumulation in CCK-KO
mice results in improved hepatic insulin sensitivity. These
differential effects on insulin action in these two genotypes
cannot be attributed to either diet composition or hyper-
caloric challenge per se in the current study. Relevant to
this, CCK1R is not detectable in the liver (18) even though
CCK-KO mice had increased hepatic insulin sensitivity in
the current study. The ﬁndings on hepatic insulin action in
CCK-KO mice are different from observations in Otsuka
Long Evans Tokushima Fatty rats during intraduodenal
CCK infusion (38). Therefore, the effect of CCK on insulin
action in the liver might not be through a direct CCK1R
pathway; i.e., some other pathway related to hepatic lipid
metabolism might be involved in insulin action. Further
studies will be required to determine whether CCK has di-
rect effects on insulin action or whether these are mediated
through CNS regulation similar to CCK effects on food
intake.
The role of CCK in the regulation of insulin secretion
and glucose homeostasis has been debated for many years.
In the present experiments, we demonstrate that CCK-KO
mice have normal glucose tolerance and normal insulin
secretion in response to arginine. Glucose-stimulated insulin
secretion is reduced in these animals but seems to be ap-
propriate for the degree of insulin sensitivity. Chronic intake
of an HFD unmasks an important action of CCK to mediate
a functional adaptation of insulin secretion to increased
adiposity. The absence of CCK action in this setting causes
glucose intolerance. Our ﬁndings also demonstrate a novel
effect of CCK to regulate insulin sensitivity, an interesting
and potentially important observation that compels further
investigation.
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